MSC Therapy for neuropathy: what the research shows.
Neuropathy — the burning, tingling, numbness, or shooting pain that comes from irritated or damaged nerves — is one of the most frustrating conditions to live with, partly because standard options often manage symptoms rather than address the nerves themselves. If you’ve been searching for alternatives, you’ve likely come across mesenchymal stromal cell (MSC) therapy. This article looks honestly at what the research actually shows so far, and, just as importantly, what it doesn’t.
A quick refresher on MSCs
Mesenchymal stromal cells, or MSCs, are a type of cell found naturally in the body. Scientific interest in them centers less on the idea that they “become” new nerves and more on the signaling molecules they release. In laboratory and animal studies, MSCs appear to participate in the body’s normal processes of regulating inflammation and supporting the local environment around tissue. MSCs used in research come from several sources, including bone marrow, fat, and umbilical cord tissue such as Wharton’s Jelly. Because nerve-related discomfort often involves inflammation and blood-flow factors, researchers have asked whether MSCs’ signaling role might be relevant to how the body maintains nerve tissue. Importantly, “relevant to research questions” is not the same as “shown to help,” and the sections below explain why that distinction matters so much here.
What the studies actually report
Here’s where honesty matters. There is a real and growing body of research on MSCs and peripheral neuropathy, especially diabetic peripheral neuropathy, but it is still early.
A 2024 systematic review and meta-analysis pulled together the controlled human trials available at the time. It found only about seven such trials, involving roughly 400 patients in total, most conducted in a single region of the world. Across those studies, researchers measured objective markers such as nerve conduction velocity and vibration perception, along with clinical symptom scores. The pooled results pointed in a favorable direction on several of these measures, and the reported side effects were generally minor and short-lived — typically pain or swelling at the injection site that resolved within days.
That sounds encouraging, and it is worth taking seriously. But the same reviewers were careful to describe the evidence as promising but preliminary. The trials were small. Follow-up periods were short, so little is known about how long any measured changes last. Study designs and cell-preparation methods varied, making it hard to compare results directly. And larger, longer, independently replicated trials — the kind that regulators and cautious clinicians look for before drawing firm conclusions — are still underway rather than complete.
Why “what the research shows” is not the same as “what it proves”
It’s easy to read a positive study summary and hear “this works.” A more accurate reading is: early research has observed changes worth investigating further, under specific conditions, in specific groups of people. Measuring an improvement in a nerve-conduction number in a small trial is a meaningful scientific signal. It is not the same as a proven, predictable outcome for an individual living with neuropathy at home. Different types of neuropathy — diabetic, chemotherapy-related, injury-related, and others — also have different underlying causes, and evidence from one does not automatically transfer to another.
Where things stand with regulation and access
In the United States, MSC preparations are not FDA-approved as a treatment for neuropathy or any related condition. Much of the human research to date has taken place through clinical trials, some outside the U.S. The FDA has also issued public advisories cautioning consumers about clinics marketing unproven cell-based products with strong promises. None of this means the science is illegitimate; it means the field is still in the research stage, and marketing claims frequently run ahead of the evidence. Anyone weighing these options should be especially skeptical of any provider guaranteeing results, quoting dramatic success rates, or describing an unproven procedure as an established cure.
Questions worth asking
If you’re exploring this area, useful questions for any clinician include: Is this being offered as part of a registered clinical trial? What specific type of neuropathy has actually been studied, and does it match mine? What does the provider claim, and can they show published, peer-reviewed evidence rather than testimonials? And how does this fit alongside — not instead of — the care I already receive for the underlying cause of my neuropathy, such as blood-sugar management? Bringing these questions to your own healthcare team helps you weigh the trade-offs realistically.
Questions?
Vivonyx’s goal is to help you understand emerging areas like this one clearly, without hype in either direction. The research on MSCs and neuropathy is genuinely interesting and genuinely unfinished, and both halves of that sentence deserve attention. If you have questions about anything covered here, or you’d like help making sense of a study or a claim you’ve encountered, reach us any time at hello@vivonyx.com.